Figure 1.
Kaplan–Meier estimates according to bone metastases for patients treated with ipilimumab plus nivolumab for (A) overall survival and (B) progression-free survival in the global cohort. Kaplan–Meier estimates according to bone metastases for patients treated with ipilimumab plus nivolumab for (C) overall survival and (D) progression-free survival in renal cell carcinoma.